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Does CMT1A homozygosity cause more severe
disease with root hypertrophy and higher
CSF proteins?
D. Pareyson, MD; D. Testa, MD; M. Morbin, MD, PhD;
A. Erbetta, MD; C. Ciano, MD; G. Lauria, MD; M. Milani, BSc;
and F. Taroni, MD
Charcot-Marie-Tooth type 1A (CMT1A) is associated with a pe-
ripheral myelin protein-22 (PMP22) gene duplication on chromo-
some 17p11.2.1 CMT1A patients have three PMP22 copies and a
gene dosage effect, leading to increased PMP22 protein expres-
sion, is the hypothesized pathogenic mechanism. Homozygosity
for the duplication has been reported in patients from three fami-
lies, with both parents carrying the duplication and transmitting
the mutation to their offspring, who had PMP22 tetrasomy and
variable disease severity.1-3
We report a homozygous CMT1A patient with rather severe
disease, high CSF proteins, and astonishing root hypertrophy.
Case report. The patient is a 45-year-old man born to first-
cousin parents. His parents, two sisters, one brother, and two sons
had pes cavus and lower limb weakness (see figure E-1A on the
Neurology Web site). He developed pes cavus and walking difficul-
ties at age 11 years, scoliosis at age 16, and slowly progressive
lower limb weakness until age 42, when he had more rapid wors-
ening with difficulty climbing stairs, loss of balance, and hand
weakness. Hearing loss started at age 33 years. On admission, he
had marked foot deformities (walking with support), moderate
scoliosis, bilateral hearing loss, muscle wasting and weakness (se-
vere distally in lower limbs, moderate in hands and thighs), gen-
eralized areflexia, distal sensory loss, and marked palpable
enlargement of ulnar nerves.
Motor nerve conduction velocities (MCV) were 10 to 12 m/s in
ulnar, median, and tibial nerves, with distal latency prolongation
(5.6, 8, 11 to 11.3 ms) and moderate-severe compound muscle
action potential (CMAP) amplitude decrease (4.4, 0.75, 0.2 to 0.4
mV). Peroneal nerve M-responses were absent. F-waves and sen-
sory action potentials could not be evoked. Asymmetry, temporal
dispersion, and conduction blocks were not detected. Audiometry
confirmed moderate sensorineural hearing loss.
CSF proteins were high (388 mg/dL; n.v. 45), raising, with
the recent worsening, the hypothesis of chronic inflammatory de-
myelinating polyradiculoneuropathy (CIDP) superimposed on
CMT1. Two courses of high-dose IV immunoglobulin were admin-
istered, as were steroids for several weeks. CSF proteins slightly
decreased (288 mg/dL), but there was no objective clinicoelectro-
physiologic improvement. Monoclonal gammopathy, antiganglio-
side, and anti-MAG antibodies were not detected.
Sural nerve biopsy, suggesting severe CMT1, revealed marked
hypertrophy (total fascicular area, 3.77 mm2; n.v., 1.34 	 0.18),
severe loss of myelinated fibers (455/mm2; n.v., 7,511 	 988),
several complex onion bulbs (758/mm2), Schwannian hyperplasia
(nuclei density, 3,250/mm2), unimodal fiber size distribution
(mean diameter, 4.4 
m), no large myelinated fiber 8 
m,
G-ratio  0.59 	 0.13 (n.v., 0.60 	 0.08), and demyelination of
19% of teased fiber internodes (CMT1A 45 years  8.1 	 3.9).4
We did not find inflammatory infiltrates, edema, focal predomi-
nance of abnormalities, immunoglobulin, or complement fragment
deposition on myelin sheaths.
On lumbar MRI, cauda equina roots were markedly hypertro-
phic, much thicker overall than the cord itself, and almost com-
pletely filled the spinal canal (figure). Root enlargement extended
to the ganglia. After gadolinium administration, a subtle enhance-
ment depicted the roots.
Molecular analyses demonstrated that the disease segregated
with the CMT1A duplication within the family. Quantitative anal-
ysis showed that the increase in PMP22 signal intensity in the
proband was larger than in his two children and in our series of
duplicated CMT1 patients, indicating homozygosity for the dupli-
cation (see figure E-1 on the Neurology Web site).5
Discussion. Disease expression variability is well known in
heterozygous CMT1A. The few reported homozygotes had neurop-
athy ranging from crippling to mild, suggesting that gene dosage
is not the only determinant of disease severity.1-3 However, PMP22
tetrasomy in our patient led to overall greater disease severity
than seen in average CMT1A. Clinical severity was comparable
with severe CMT1A; hearing loss, rare in CMT1A, occurred.
CMAPs and MCV were in the lower CMT1A range (upper limb
MCV  7 to 36 m/s; mean, 19.8 	 5.2, in our 78 CMT1A patients).
Nerve biopsy showed more severe demyelination and greater loss
of myelinated fibers than usually seen in CMT1A.4 CSF proteins
were much higher than those observed in CMT1A (20 to 122
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the May 27 issue to find the link for this article.
Figure. MRI of the lumbosacral spine. Midline sagittal
(A), coronal (B), and axial (C) spin-echo T2-weighted im-
ages show thickened nerve roots that completely fill the
dural sac. Compare the size of the spinal cord (black ar-
rowheads in A) with the enlarged cauda equina. Marked
decrease of CSF causes poor definition of the conus and
proximal nerve roots. In C (L4-L5 level), the white arrow-
heads indicate the hypertrophic ganglia.
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mg/dL; mean, 58, in 13 of our patients). Finally, he had astonish-
ing root hypertrophy.
Hypertrophy of spinal roots, rarely symptomatic, has been oc-
casionally reported in hypertrophic neuropathy (CMT1, Dejerine–
Sottas disease, CIDP).6,7 Most of these patients were not
genetically characterized, and the true incidence of root hypertro-
phy in CMT1A is unknown. Therefore, the mechanism whereby
some patients show greater hypertrophy is unclear. In our pa-
tient, it is likely that PMP22 tetrasomy was a further stimulus to
nerve hypertrophy. Not only were the cauda equina roots hyper-
trophied but also the ulnar nerves were markedly enlarged, and
the biopsied sural nerve showed relevant hypertrophic changes.
The onion bulb number was comparable with that of a series of 20
CMT1A patients,4 but Schwann cell hyperplasia was considerable,
indicating the presence of more complex onion bulbs than in al-
most all these patients.4 The somewhat rapid deterioration during
the past 3 years and high CSF proteins suggested CIDP superim-
posed on CMT1. However, we found no confirmatory evidence in
laboratory, electrophysiologic, and morphologic findings. Root hy-
pertrophy is the likely cause of increased CSF proteins, probably
through leakage from enlarged roots and partial block of CSF
circulation.
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Hemicrania horologica (“clock-like
hemicrania”)
Franco Granella, MD; and Giovanni D’Andrea, MD
In 1747, the German physician Oppermann described a peculiar
clinical patient.1 A 35-year-old woman suffered from excruciating
daily headache attacks, lasting 15 minutes, which occurred ex-
actly every hour, day and night, with extraordinary precision.
Oppermann defined this peculiar headache “hemicrania horo-
logica” (clocklike hemicrania). It has been suggested2 that Opper-
mann’s case was the first known of chronic paroxysmal
hemicrania (CPH). We describe here a similar case.1
Case report. A 69-year-old man was headache-free until the
age of 66, when he began to complain of strictly unilateral head-
ache attacks on the left side. The pain started behind the ear and
then spread ipsilaterally over the temporal and zygomatic regions
or over the neck and shoulder. The pain, of throbbing quality, was
mild at the beginning of the attacks and afterward became severe,
reaching a 5-minute plateau before slowly subsiding. Photophobia,
phonophobia, nausea, and vomiting were lacking, as was any local
autonomic sign except for modest bilateral facial sweating. No
trigger factors were detectable. The attacks, lasting 15 minutes,
occurred exactly every 60 minutes, day and night, i.e., the subse-
quent attack occurred exactly 60 minutes after the end of the
previous one. During 24 hours, therefore, 19 attacks occurred
(figure). At the beginning, the attacks occurred only 1 day every 2
weeks or 1 month; after 6 months, however, the headache oc-
curred daily. The patient had been unsuccessfully treated with
paroxetine and corticosteroid injection of the left great occipital
nerve. He had discovered by himself that a small amount of nime-
sulide (a nonsteroidal anti-inflammatory drug [NSAID] of wide-
spread use in Italy), taken before sleeping, was able to avoid the
nocturnal attacks. Therefore, he took this drug every night before
going to bed.
Medical history was remarkable for the removal of a prostatic
cancer at age 68 years. Physical and neurologic examinations
were unremarkable, except for marked tenderness at the palpa-
tion of the left great occipital nerve. A psychiatric interview and
the Minnesota Multiphasic Personality Inventory 2 were normal.
The routine blood examinations, including erythrocyte sedimenta-
tion rate (ESR), were normal. Brain MRI was normal, too.
At our first observation, the patient was asked to withdraw
from nimesulide and to complete a headache diary for 1 week.
During this period, the attacks occurred, as previously described
by the patient, every 60 (	 2) minutes, with absolute regularity,
and lasted 15 minutes.
We treated the patient with low-dose indomethacin (25 mg
twice daily) for 1 week, which resulted in a prompt disappearance
of the attacks. However, the attacks occurred again 12 hours after
drug withdrawal. The same effect was obtained with other
NSAIDs, such as ibuprofen (600 mg twice daily) and nimesulide
(100 mg twice daily). We treated the patient with nimesulide, 100
mg twice daily, for 3 months and thereafter withdrew the drug.
The attacks reappeared soon after. The treatment was restarted
and continued for another 4 months, when the patient spontane-
ously interrupted it, without any recurrence. Subsequently, he has
been headache-free for 6 months.
Discussion. Our patient is remarkably similar to Opper-
mann’s.1 Are both cases of CPH? Our patient does not fulfill all the
Figure. Distribution of the headache attacks during the
24-hour period (  attacks lasting 15 minutes).
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